Becker's ASC Review reaches 609,000 monthly visitors including ASC leaders, gastroenterologists, and health system decision-makers — the exact stakeholders who influence clinical adoption of new diagnostic technologies like HelioLiver.
Becker's ASC Review reports that Quest Diagnostics will offer HelioLiver, Helio Genomics' blood-based test designed for early detection of hepatocellular carcinoma, through its nationwide provider network starting April 2026. The article, which was subsequently syndicated by NewsBreak to 13.9 million readers, highlights the test's availability through Quest's established ordering and EHR systems.